SNP_ID	Allele	Gene	Drug	Evidence_level	Efficacy	Dosage	Toxicity	Genotype	Description
rs11209716	T > C	PTGER3	Ace Inhibitors, Plain	Level 3	-	-	decreased	CC	                Patients with the CC genotype and hypertension who are treated with ACE inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk of cough when treated with ACE inhibitors.
rs2016848	G > A	MME	Ace Inhibitors, Plain	Level 3	-	-	increased	AA	                Patients with the AA genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cough with ACE inhibitor treatment.
rs2108622	C > T	CYP4F2	acenocoumarol	Level 1B	-	increased	-	TT	                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.
rs1056892	G > A	CBR3	anthracyclines and related substances	Level 2B	-	-	decreased	AA	                Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.
rs1042522	C > G	TP53	antineoplastic agents	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs1801133	G > A	CLCN6	antipsychotics	Level 3	-	-	increased	AA	                Patients with the AA genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.
rs1800460	C > T	TPMT	azathioprine	Level 1A	-	-	increased	CT	                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs1800462	C > G	TPMT	azathioprine	Level 1A	-	-	increased	GG	                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.
rs2297595	T > C	DPYD	capecitabine	Level 2A	-	-	increased	CC	                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.
rs1801133	G > A	CLCN6	carboplatin	Level 2A	increased	-	increased	AA	                Patients with AA genotype may have 1) increased likelihood of response 2) increased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patients response to carboplatin.
rs1799853	C > T	CYP2C9	celecoxib	Level 3	decreased	-	-	CT	                Patients with the CT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to celecoxib.
rs2228001	G > T	XPC	cisplatin	Level 1B	-	-	decreased	TT	                Patients with the TT genotype may have a decreased but not non-existent risk for toxicity with cisplatin treatment as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs1800460	C > T	TPMT	cisplatin	Level 3	-	-	increased	CT	                Patients with the TC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.
rs1042522	C > G	TP53	cisplatin	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs1801133	G > A	MTHFR	cisplatin	Level 3	increased	-	increased	AA	                Patients with the AA genotype may have: 1) increased likelihood of response to chemotherapy, 2) increased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotypes AG or GG. Other genetic and clinical factors may also influence a patients response to cisplatin.
rs1695	A > G	GSTP1	cisplatin	Level 3	decreased	-	-	AG	                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.
rs1695	A > G	GSTP1	cisplatin	Level 3	decreased	-	-	AG	                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.
rs9332377	C > T	COMT	cisplatin	Level 1B	-	-	increased	CT	                Patients with the CT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.
rs1042522	C > G	TP53	cyclophosphamide	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs1801133	G > A	MTHFR	cyclophosphamide	Level 2A	-	-	increased	AA	                Patients with the AA genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to cyclophosphamide.
rs1695	A > G	GSTP1	cyclophosphamide	Level 2A	increased	-	-	AG	                Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.
rs1695	A > G	GSTP1	cyclophosphamide	Level 3	decreased	-	-	AG	                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.
rs1695	A > G	GSTP1	cyclophosphamide	Level 3	decreased	-	-	AG	                Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.
rs3745274	G > T	CYP2B6	cyclophosphamide	Level 3	-	-	decreased	GT	                Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patients risk for venoocclusive disease of the liver.
rs3745274	G > T	CYP2B6	cyclophosphamide	Level 3	-	decreased	-	GT	                Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.
rs3745274	G > T	CYP2A7P1	efavirenz	Level 2A	-	-	increased	GT	                Patients with the GT genotype may have an increased risk of efavirenz-induced side effects (central nervous symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs1695	A > G	GSTP1	epirubicin	Level 2A	increased	-	-	AG	                Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.
rs1042522	C > G	TP53	fluorouracil	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs1801133	G > A	MTHFR	fluorouracil	Level 2A	-	-	increased	AA	                Patients with the AA genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the GG genotype. However, conflicting finding of no-association for this genotype has also been reported. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.
rs1695	A > G	GSTP1	fluorouracil	Level 3	-	-	decreased	AG	                Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for hematological toxicity when exposed to fluorouracil.
rs2297595	T > C	DPYD	fluorouracil	Level 2A	-	-	increased	CC	                Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.
rs1800460	C > T	TPMT	mercaptopurine	Level 1A	-	-	increased	CT	                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs1800462	C > G	TPMT	mercaptopurine	Level 1A	-	-	increased	GG	                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.
rs1801133	G > A	MTHFR	mercaptopurine	Level 3	-	-	-	AA	                Patients with the AA genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patients risk for toxicity to mercaptopurine.
rs1801133	G > A	MTHFR	methotrexate	Level 1B	-	-	increased	AA	                Patients with the AA genotype with Leukemia or Lymphoma who are treated with methotrexate regimens may have an increased risk and increased severity of mucositis, as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patients risk of oral mucositis.
rs1801133	G > A	MTHFR	methotrexate	Level 3	-	-	increased	AA	                Patients with the AA genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype (though this association has not been found in all studies). There does not seem to be an association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patients risk for adverse events with methotrexate treatment.
rs1801133	G > A	MTHFR	methotrexate	Level 3	-	-	increased	AA	                Patients with the AA genotype and non-Hodgkin lymphoma who are treated with methotrexate may have an increased risk of mucositis, thrombocytopenia and hepatic toxicity as compared to patients with the GG genotype. This association was not found in pediatric patients with non-Hodgkin lymphoma who were treated with methotrexate. Other genetic and clinical factors may also influence a patients risk for methotrexate-induced toxicity.
rs1801133	G > A	MTHFR	methotrexate	Level 3	decreased	-	-	AA	                Patients with the AA genotype with non-hodgkin lymphoma who are treated with methotrexate may be less likely to have event free survival at 5 years as compared to patients with the GG genotype. This genotype was not associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the GG genotype. Other genetic and clinical factors may also influence a patients response to methotrexate treatment.
rs1801133	G > A	MTHFR	methotrexate	Level 3	decreased	decreased	increased	AA	                Patients with the AA genotype and Leukemia who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate as compared to patients with the GG genotype. This association has been contradicted or not found in several studies. Other genetic and clinical factors may also influence a patients risk for toxicity and response with methotrexate treatment.
rs1801133	G > A	MTHFR	methotrexate	Level 3	-	-	decreased	AA	                Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk Graft vs Host disease and efficacy of methotrexate treatment.
rs1801133	G > A	MTHFR	nitrous oxide	Level 3	-	-	-	AA	                Patients with the AA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients homocysteine levels after nitrous oxide anesthesia.
rs1695	A > G	GSTP1	oxaliplatin	Level 3	-	-	increased	AG	                Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.
rs1042522	C > G	TP53	paclitaxel	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs12979860	C > T	IL28B	peginterferon alfa-2a	Level 1A	decreased	-	-	TT	                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.
rs8099917	T > G	IL28B	peginterferon alfa-2a	Level 1B	decreased	-	-	GG	                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.
rs12979860	C > T	IL28B	peginterferon alfa-2b	Level 1A	decreased	-	-	TT	                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.
rs8099917	T > G	IL28B	peginterferon alfa-2b	Level 1B	decreased	-	-	GG	                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.
rs2108622	C > T	CYP4F2	phenprocoumon	Level 1B	-	increased	-	TT	                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.
rs1799853	C > T	CYP2C9	phenytoin	Level 3	-	-	increased	CT	                Patients with the CT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to phenytoin.
rs1695	A > G	GSTP1	Platinum compounds	Level 3	-	-	increased	AG	                Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.
rs1800460	C > T	TPMT	purine analogues	Level 1A	-	-	increased	CT	                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs1800462	C > G	TPMT	purine analogues	Level 1A	-	-	increased	GG	                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.
rs12979860	C > T	IL28B	ribavirin	Level 1A	decreased	-	-	TT	                Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.
rs8099917	T > G	IL28B	ribavirin	Level 1B	decreased	-	-	GG	                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.
rs1800460	C > T	TPMT	thioguanine	Level 1A	-	-	increased	CT	                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs1800462	C > G	TPMT	thioguanine	Level 1A	-	-	increased	GG	                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.
rs7294	C > T	VKORC1	warfarin	Level 1B	-	increased	-	CT	                Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.
rs2108622	C > T	CYP4F2	warfarin	Level 1B	-	increased	-	TT	                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.
rs1799853	C > T	CYP2C9	warfarin	Level 1A	-	decreased	-	CT	                Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients dose of warfarin.
